Article

Increasing antiretroviral drug access for children with HIV infection.

PEDIATRICS (impact factor: 4.47). 04/2007; 119(4):838-45. DOI:10.1542/peds.2007-0273 pp.838-45
Source: PubMed

ABSTRACT Although there have been great gains in the prevention of pediatric HIV infection and provision of antiretroviral therapy for children with HIV infection in resource-rich countries, many barriers remain to scaling up HIV prevention and treatment for children in resource-limited areas of the world. Appropriate testing technologies need to be made more widely available to identify HIV infection in infants. Training of practitioners in the skills required to care for children with HIV infection is required to increase the number of children receiving antiretroviral therapy. Lack of availability of appropriate antiretroviral drug formulations that are easily usable and inexpensive is a major impediment to optimal care for children with HIV. The time and energy spent trying to develop liquid antiretroviral formulations might be better used in the manufacture of smaller pill sizes or crushable tablets, which are easier to dispense, transport, store, and administer to children.

0 0
 · 
0 Bookmarks
 · 
16 Views
  • Source
    Article: Ensuring the involvement of children in the evaluation of new tuberculosis treatment regimens.
    William J Burman, Mark F Cotton, Diana M Gibb, A Sarah Walker, Andrew A Vernon, Peter R Donald
    PLoS Medicine 09/2008; 5(8):e176. · 16.27 Impact Factor
  • Source
    Article: Risk of triple-class virological failure in children with HIV: a retrospective cohort study.
    Hannah Castro, Ali Judd, Diana M Gibb, Karina Butler, Rebecca K Lodwick, Ard van Sighem, Jose T Ramos, Josiane Warsawski, Claire Thorne, Antoni Noguera-Julian, Niels Obel, Dominique Costagliola, Pat A Tookey, Céline Colin, Jesper Kjaer, Jesper Grarup, Genevieve Chene, Andrew Phillips
    [show abstract] [hide abstract]
    ABSTRACT: In adults with HIV treated with antiretroviral drug regimens from within the three original drug classes (nucleoside or nucleotide reverse transcriptase inhibitors [NRTIs], non-NRTIs [NNRTIs], and protease inhibitors), virological failure occurs slowly, suggesting that long-term virological suppression can be achieved in most people, even in areas where access is restricted to drugs from these classes. It is unclear whether this is the case for children, the group who will need to maintain viral suppression for longest. We aimed to determine the rate and predictors of triple-class virological failure to the three original drugs classes in children. In the Collaboration of Observational HIV Epidemiological Research Europe, the rate of triple-class virological failure was studied in children infected perinatally with HIV who were aged less than 16 years, starting antiretroviral therapy (ART) with three or more drugs, between 1998 and 2008. We used Kaplan-Meier and Cox regression methods to investigate the risk and predictors of triple-class virological failure after ART initiation. Of 1007 children followed up for a median of 4·2 (IQR 2·4-6·5) years, 237 (24%) were triple-class exposed and 105 (10%) had triple-class virological failure, of whom 29 never had a viral-load measurement less than 500 copies per mL. Incidence of triple-class virological failure after ART initiation increased with time, and risk by 5 years after ART initiation was 12·0% (95% CI 9·4-14·6). In multivariate analysis, older age at ART initiation was associated with increased risk of failure (p=0·02). Of 686 children starting ART with NRTIs and either a NNRTI or ritonavir-boosted protease inhibitor, the rate of failure was higher than in adults with heterosexually transmitted HIV (hazard ratio 2·2 [95% CI 1·6-3·0, p<0·0001]). Findings highlight the challenges of attaining long-term viral suppression in children who will be taking life-long ART. Early identification of children not responding to ART, adherence support, particularly for children and adolescents aged 13 years or older starting ART, and ART simplification strategies are all needed to attain and sustain virological suppression. UK Medical Research Council award G0700832.
    The Lancet 05/2011; 377(9777):1580-7. · 38.28 Impact Factor
  • Source
    Article: Risk factors associated with increased mortality among HIV infected children initiating antiretroviral therapy (ART) in South Africa.
    Brian C Zanoni, Thuli Phungula, Holly M Zanoni, Holly France, Margaret E Feeney
    [show abstract] [hide abstract]
    ABSTRACT: To identify demographic and clinical risk factors associated with mortality after initiation of antiretroviral therapy (ART) in a cohort of human immunodeficiency (HIV) infected children in KwaZulu-Natal, South Africa. We performed a retrospective cohort study of 537 children initiating antiretroviral therapy at McCord Hospital in KwaZulu-Natal, South Africa. Data were extracted from electronic medical records and risk factors associated with mortality were assessed using Cox regression analysis. Overall there were 47 deaths from the cohort of 537 children initiating ART with over 991 child-years of follow-up (median 22 months on ART), yielding a mortality rate of 4.7 deaths per 100 child years on ART. Univariate analysis indicated that mortality was significantly associated with lower weight-for-age Z-score (p<0.0001), chronic diarrhea (p = 0.0002), lower hemoglobin (p = 0.002), age <3 years (p = 0.003), and CD4% <10% (p = 0.005). The final multivariable Cox proportional hazards mortality model found age less than 3 years (p = 0.004), CD4 <10% (p = 0.01), chronic diarrhea (p = 0.03), weight-for-age Z-score (<0.0001) and female gender as a covariate varying with time (p = 0.03) all significantly associated with mortality. In addition to recognized risk factors such as young age and advanced immunosuppression, we found female gender to be significantly associated with mortality in this pediatric ART cohort. Future studies are needed to determine whether intrinsic biologic differences or socio-cultural factors place female children with HIV at increased risk of death following initiation of ART.
    PLoS ONE 01/2011; 6(7):e22706. · 4.09 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

antiretroviral therapy
 
appropriate antiretroviral drug formulations
 
Appropriate testing technologies
 
barriers
 
children
 
crushable tablets
 
dispense
 
HIV infection
 
HIV prevention
 
infants
 
liquid antiretroviral formulations
 
major impediment
 
pediatric HIV infection
 
practitioners
 
resource-limited areas
 
smaller pill sizes
 
usable